Blog

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Photo taken from Vivek Subbiah/Twitter

Oct 5, 2023, 17:41

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on X/Twitter:

“ANNOUNCEMENT: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6. Super thrilled to co-Chair a very important session on Tumor Agnostic and Precision Medicine with Dr. Francesco Pignatti, Head of Oncology, Haematology, Diagnostics – Safety and Efficacy Sector at European Medicines Agency (EMA).
What are the current roadblocks to histology agnostic biomarker driven approvals?
Hear directly from speakers from US FDA, EMA and from the patient perspective.”

For more information click here.
Source: Vivek Subbiah/Twitter.

Announcement cancer Diagnostics EMA ESMO European Medicines Agency Francesco Pignatti Hematology OncoDaily Oncology patient Precision Medicine US FDA Vivek Subbiah

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage